©The Author(s) 2023.
World J Clin Cases. Oct 16, 2023; 11(29): 6984-6994
Published online Oct 16, 2023. doi: 10.12998/wjcc.v11.i29.6984
Published online Oct 16, 2023. doi: 10.12998/wjcc.v11.i29.6984
Table 1 Cancer type, stage, and location of obstruction in malignant biliary obstruction
| MBO group (n = 56) | |
| Etiology of MBO | |
| Pancreatic cancer | 24 (42.9%) |
| Stage I/II/III/IV | 1/6/3/14 |
| Ampulla of Vater cancer | 13 (23.2%) |
| Adenoma | 2 |
| Cancer, stage I/II/III/IV | 4/3/3/1 |
| CBD cancer | 6 (10.7%) |
| Stage I/II/III/IV | 1/4/0/1 |
| Klatskin tumor | 3 (5.4%) |
| Stage I/II/III/IV | 0/0/0/3 |
| Metastatic tumor | 6 (10.7%) |
| Hepatocellular carcinoma | 2 (3.6%) |
| Gallbladder cancer | 2 (3.6%) |
| Stage I/II/III/IV | 0/0/0/2 |
| Location of obstruction | |
| Distal EHD | 46 (82.1%) |
| Perihilar obstruction | 10 (17.9%) |
| Bismuth-Corlette type I | 4 |
| Bismuth-Corlette type II | 6 |
- Citation: Tsou YK, Su YT, Lin CH, Liu NJ. Acute cholangitis: Does malignant biliary obstruction vs choledocholithiasis etiology change the clinical presentation and outcomes? World J Clin Cases 2023; 11(29): 6984-6994
- URL: https://www.wjgnet.com/2307-8960/full/v11/i29/6984.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i29.6984